Study

EORTC-1726-QLG

Evaluating the use of the E-PRO measures for improving inter-rater reliability of CTCAE ratings

Study documentation Back to result

Trial Status

Recruiting

Dates

Data management at EORTC

None

Design

QoL Non Mod Dev.
Not randomized / N.A.

Targeted Sample size

Treatment

None

Study Staff

  • Bernhard Holzner (Study Coordinator), A.O Landeskrankenhaus - Innsbruck Universitaetsklinik, Innsbruck
  • Melanie Beauvois (Clinical Operations Manager), EORTC Headquarters, Brussels
  • Corneel Coens (Statistician), EORTC Headquarters, Brussels
  • Lisa Wintner (Study Co-Coordinator), A.O Landeskrankenhaus - Innsbruck Universitaetsklinik, Innsbruck

Type of cancer

  • Acute Myelogenous Leukemia
  • Anal
  • Biliary Tract
  • Bladder
  • Brain
  • Breast
  • Cervical
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • Colon
  • Colorectal
  • Endometrium
  • Esophageal
  • Fallopian Tube
  • Gastric
  • Head and Neck
  • Hodgkins Disease
  • Kidney
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Multiple Myeloma
  • Myelodysplastic Syndroms
  • Neuroendocrine
  • Non Hodgkins Lymphoma
  • Osteosarcoma
  • Ovarian
  • Pancreatic
  • Penile
  • Primary Cutaneous Lymphomas
  • Prostate
  • Rectal
  • Refractory Lymphoid Neoplasms
  • Soft Tissue and Bone Sarcoma
  • Solid Tumors, Unspecified
  • Testicular
  • Thymoma
  • Thyroid
  • Uterine
  • Uveal Melanoma
  • Vaginal
  • Vulvar

Participating groups

  • EORTC Quality of Life Group

Protocol summary

http://clinicaltrials.gov/study/

NCT number